A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Clinical trial NCT06539208 · RECRUITING
Trial details
- NCT number
- NCT06539208
- Sponsor
- YolTech Therapeutics Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-23
- Primary completion
- 2025-06-30
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.